These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16302899)

  • 1. The impact of cardiac resynchronization therapy on ventricular tachycardia/fibrillation: an analysis from the combined Contak-CD and InSync-ICD studies.
    McSwain RL; Schwartz RA; DeLurgio DB; Mera FV; Langberg JJ; León AR
    J Cardiovasc Electrophysiol; 2005 Nov; 16(11):1168-71. PubMed ID: 16302899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of ventricular tachycardias based on time and frequency domain analyses of cycle length variability in patients with implantable cardioverter defibrillator.
    Sierra G; Molin F; Savard P; Soucy B; Nadeau R
    Can J Cardiol; 1999 Nov; 15(11):1223-8. PubMed ID: 10579736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators.
    Ermis C; Seutter R; Zhu AX; Benditt LC; VanHeel L; Sakaguchi S; Lurie KG; Lu F; Benditt DG
    J Am Coll Cardiol; 2005 Dec; 46(12):2258-63. PubMed ID: 16360055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic effect of reverse ventricular remodeling induced by cardiac resynchronization therapy: the InSync ICD (Implantable Cardioverter-Defibrillator) Italian Registry.
    Di Biase L; Gasparini M; Lunati M; Santini M; Landolina M; Boriani G; Curnis A; Bocchiardo M; Vincenti A; Denaro A; Valsecchi S; Natale A; Padeletti L;
    J Am Coll Cardiol; 2008 Oct; 52(18):1442-9. PubMed ID: 19017510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients.
    Wilkoff BL; Hess M; Young J; Abraham WT
    J Cardiovasc Electrophysiol; 2004 Sep; 15(9):1002-9. PubMed ID: 15363071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ;
    J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials.
    Pires LA; Abraham WT; Young JB; Johnson KM;
    Am Heart J; 2006 Apr; 151(4):837-43. PubMed ID: 16569543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter-defibrillator patients who are upgraded and respond to cardiac resynchronization therapy have less ventricular arrhythmias compared with nonresponders.
    Thijssen J; Borleffs CJ; Delgado V; van Rees JB; Mooyaart EA; van Bommel RJ; van Erven L; Boersma E; Bax JJ; Schalij MJ
    J Am Coll Cardiol; 2011 Nov; 58(22):2282-9. PubMed ID: 22093504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
    Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
    J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
    Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
    Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between New York Heart Association class change and ventricular tachyarrhythmia occurrence in patients treated with cardiac resynchronization plus defibrillator.
    Lepillier A; Piot O; Gerritse B; Copie X; Lavergne T; Paziaud O; Lascault G; Waintraub X; Otmani A; Le Heuzey JY
    Europace; 2009 Jan; 11(1):80-5. PubMed ID: 18952828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cardiac resynchronisation therapy on occurrence of ventricular arrhythmia in patients with implantable cardioverter defibrillators undergoing upgrade to cardiac resynchronisation therapy devices.
    Lin G; Rea RF; Hammill SC; Hayes DL; Brady PA
    Heart; 2008 Feb; 94(2):186-90. PubMed ID: 17761506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of appropriate defibrillator therapy among patients with an implantable defibrillator that delivers cardiac resynchronization therapy.
    Desai AD; Burke MC; Hong TE; Kim S; Salem Y; Yong PG; Knight BP
    J Cardiovasc Electrophysiol; 2006 May; 17(5):486-90. PubMed ID: 16684019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
    Vyas AK; Guo H; Moss AJ; Olshansky B; McNitt SA; Hall WJ; Zareba W; Steinberg JS; Fischer A; Ruskin J; Andrews ML;
    J Am Coll Cardiol; 2006 Feb; 47(4):769-73. PubMed ID: 16487843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of first ventricular tachycardia cycle length on rate of ventricular arrhythmia recurrence in patients with implantable cardioverter-defibrillator.
    Arya A; Haghjoo M; Nikoo MH; Dehghani MR; Fazelifar AF; Sadr-Ameli MA
    J Electrocardiol; 2006 Oct; 39(4):404-8. PubMed ID: 16895771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.
    Klein G; Lissel C; Fuchs AC; Gardiwal A; Oswald H; Desousa M; Pichlmaier AM; Lichtinghagen R; Geerlings H; Lippolt P; Niehaus M; Drexler H; Korte T
    Europace; 2006 Aug; 8(8):618-24. PubMed ID: 16864615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between left ventricular ejection fraction post-cardiac resynchronization treatment and subsequent implantable cardioverter defibrillator therapy for sustained ventricular tachyarrhythmias.
    Manfredi JA; Al-Khatib SM; Shaw LK; Thomas L; Fogel RI; Padanilam B; Rardon D; Vatthyam R; Gemma LW; Golden K; Prystowsky EN
    Circ Arrhythm Electrophysiol; 2013 Apr; 6(2):257-64. PubMed ID: 23443618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of implantable cardioverter defibrillators in the secondary prevention of malignant ventricular arrhythmias: lessons from large studies].
    Anadolu Kardiyol Derg; 2001 Mar; 1(1):43-7, AXIV. PubMed ID: 12132492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy: clinical presentation, risk stratification and results of long-term follow-up.
    Pezawas T; Stix G; Kastner J; Schneider B; Wolzt M; Schmidinger H
    Int J Cardiol; 2006 Mar; 107(3):360-8. PubMed ID: 16503259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.